Sydney, May 3, 2026, 23:02 AEST
CSL Limited picked up another 110,004 shares on April 30, spending A$13.69 million, according to a May 1 ASX filing, as the biotech company keeps buying its own stock while trading close to multi-year lows. Up to that point, CSL had already repurchased 6,242,085 shares for a total of A$1.044 billion. The company previously announced the buyback could go as high as US$750 million and is set to continue until June 30.
Timing matters here. CSL shares ended Friday at A$124.84, edging up 0.38%. Still, that’s just above their 52-week low of A$123.88—less than half the 52-week high of A$275.79, according to market data.
Management doesn’t have many quick tools, but a buyback stands out while investors hold out for clearer earnings. With an on-market buyback, the company repurchases its own stock on the exchange—shrinking the share count, though that move only goes so far unless the underlying business finds its footing.
CSL’s half-year numbers weren’t pretty. Revenue slipped 4% to US$8.3 billion, with reported net profit after tax tumbling 81% to US$401 million on a constant-currency basis—removing the noise from exchange rates. Underlying NPATA, which leaves out acquisition amortisation and big one-offs, dropped 7% to US$1.9 billion. “Clearly not satisfied,” was how Chief Financial Officer Ken Lim summed it up. Still, CSL held to its fiscal 2026 outlook, sticking with a forecast of 2% to 3% revenue growth and 4% to 7% NPATA growth, before restructuring and impairments.
Gordon Naylor, who stepped in as interim chief executive and managing director on Feb. 11 following Paul McKenzie’s retirement, now takes the reins. The former CSL executive and non-executive director named CSL’s strategic transformation as his “immediate priority,” pointing to close collaboration with both the board and the leadership team.
Flu vaccines delivered the most recent blow. Last month, Reuters said the U.S. military had dropped its flu vaccine mandate, sparking worries about demand from a major institutional customer. Marc Jocum at GlobalXETFs described the move as “incremental pressure at the worst possible time.” At the same time, Vantage Markets’ Hebe Chen flagged a “lack of clarity” regarding CSL’s outlook. According to Reuters, CSL Seqirus pulled in roughly US$2.17 billion in revenue for fiscal 2025, making up about 14% of the company’s overall haul. Reuters
CSL’s vaccine division now faces a tighter contest. Sanofi, GSK, and CSL Seqirus all rank among top seasonal flu shot producers, but even small changes in public-sector orders can hit hard when uptake is soft.
Still, the drawbacks are hard to miss. Buybacks shrink the share count, sure, but they don’t address sluggish U.S. immunisation uptake or eliminate the execution risk tied to a restructuring that’s set to spin off Seqirus, slash headcount by as much as 15%, and hit annual pre-tax savings targets of US$500 million to US$550 million by fiscal 2028.
CSL’s ASX page keeps logging buyback updates—May 1, April 30, April 29—giving investors a running tally of capital moves. The tougher call? Whether Naylor can parlay that show of support into a rebound across vaccines, plasma therapies, and sentiment before the buyback period wraps up.
